Bruce Jackson

Ryan Zimmerman

Joshua Jennings

Kristen Kluska

Vernon Bernardino

Josh Jennings

Ramakanth Swayampakula

- Humacyte, Inc. (HUMA) and its subsidiary, Humacyte Global, Inc., entered into **Amendment No. 2 to the Revenue Interest Purchase Agreement** on **September 17, 2025**.  **[1818382_0001104659-25-090963_tm2526406d1_ex10-1.htm:0]** **[1818382_0001104659-25-090963_tm2526406d1_8k.htm:1]** 
- The company will make a **$50.0 million repayment** under the Purchase Agreement, funded from existing restricted cash.  **[1818382_0001104659-25-090963_tm2526406d1_8k.htm:1]** 
- This amendment removes the obligation to maintain **$50.0 million of restricted cash**, unless the Purchase Agreement is not fully repaid by **December 31, 2025**, in which case **$12.5 million** will be required.  **[1818382_0001104659-25-090963_tm2526406d1_8k.htm:1]** 
- Humacyte now has the option to exercise its call option at a discounted repurchase price of **$95.5 million** if exercised on or prior to **December 31, 2025**.  **[1818382_0001104659-25-090963_tm2526406d1_8k.htm:1]** **[1818382_0001104659-25-090963_tm2526406d1_ex10-1.htm:37]** 
- Up to **$7.5 million** of this call option may be satisfied through the issuance of the company's common stock.  **[1818382_0001104659-25-090963_tm2526406d1_8k.htm:1]**

Humacyte (HUMA)